Arrowhead Pharmaceuticals (ARWR) Liabilities and Shareholders Equity (2010 - 2026)

Arrowhead Pharmaceuticals' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $2.3 billion for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 44.15% year-over-year to $2.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.6 billion (up 43.98% YoY) and the FY2025 annual result came in at $1.4 billion, up 21.54% from the prior year.
• Liabilities and Shareholders Equity was $2.3 billion for Q1 2026 at Arrowhead Pharmaceuticals, up from $1.6 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $2.3 billion in Q1 2026 and bottomed at $626.3 million in Q4 2023.
• A 5-year average of $1.1 billion and a median of $891.5 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity retreated 29.75% — and 2025, when it jumped 64.74%.
• Arrowhead Pharmaceuticals' Liabilities and Shareholders Equity stood at $891.5 million in 2022, then slipped by 29.75% to $626.3 million in 2023, then surged by 61.86% to $1.0 billion in 2024, then surged by 58.25% to $1.6 billion in 2025, then soared by 41.4% to $2.3 billion in 2026.
• Business Quant data shows ARWR's Liabilities and Shareholders Equity at $2.3 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.4 billion in Q3 2025.